<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity. Both ketamine and serotonergic psychedelics (SPs) have been studied as novel treatments for depression, particularly Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). Promising results and demonstrated benefits in preliminary research have garnered these compounds much attention. Noted for their rapidity of onset, as well as consistently observed reductions in depressive symptoms and suicidal ideation, ketamine and SPs alike offer hope where traditional antidepressants may fall short.
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |